TLDRs;
- AI partnership targets next-generation DNA editing medicines
- Lilly expands push into AI-driven drug discovery platform
- Deal focuses on advanced gene editing beyond CRISPR systems
- Profluent combines open-source biotech with commercial AI development strategies
Eli Lilly has strengthened its position in the rapidly evolving field of AI-driven biotechnology by entering a major partnership with startup Profluent.
The US pharmaceutical giant confirmed on April 28 that it has signed a deal valued at up to $2.25 billion to co-develop next-generation DNA-editing medicines powered by artificial intelligence.
Under the agreement, Eli Lilly will secure exclusive rights to any therapeutic products that emerge from the collaboration. However, the companies did not disclose the upfront payment or specify which diseases the research will initially target, leaving room for broad exploration across genetic medicine.
The move underscores Lilly’s growing ambition to integrate AI into its drug discovery pipeline at a time when the industry is racing to improve speed, precision, and success rates in clinical development.
Pushing Beyond CRISPR Limits
At the core of the collaboration is a next-generation gene-editing approach built around AI-designed proteins known as recombinases. These molecular tools are capable of inserting long segments of DNA, measured in kilobases, at precise locations in the genome.
https://x.com/business/status/2049087530587316558
This represents a significant leap beyond traditional CRISPR/Cas9 systems, which typically make smaller, more localized genetic edits. Researchers involved in the project see recombinases as a potential breakthrough for treating complex genetic diseases that require larger DNA modifications.
Profluent CEO Ali Madani has described kilobase-scale DNA editing as a “holy grail” in genetic medicine, highlighting the long-standing challenge scientists have faced in achieving safe and precise large-scale genome modification.
Lilly Deepens AI Strategy
This latest agreement is not an isolated move but part of Eli Lilly’s broader strategy to embed artificial intelligence into its research and development operations. Earlier in January, the company signed a separate $1.12 billion collaboration with Seamless Therapeutics, also focused on recombinase-based therapies, including potential treatments for hearing loss.
By adding Profluent to its growing network of AI biotech partners, Lilly is positioning itself at the forefront of a field that many believe could reshape how medicines are discovered and designed.
Despite the momentum, the sector remains in its early stages. No AI-designed drug has yet received regulatory approval, although numerous candidates are currently progressing through clinical trials.
Open-Source Meets Commercial Science
Profluent is taking a hybrid approach to biotechnology innovation. The company is transitioning from identifying natural proteins to designing entirely new ones using AI, a methodology it refers to as “programmable biology.”
While the Eli Lilly deal focuses on proprietary gene-editing tools, Profluent has also embraced open science. It previously released OpenCRISPR-1, an AI-generated gene-editing system that is available for both ethical research and commercial licensing.
In laboratory tests involving human cells, OpenCRISPR-1 demonstrated editing performance comparable to SpCas9, one of the most widely used CRISPR enzymes. Notably, it also reduced unintended genetic modifications by approximately 95%, a key safety improvement in genome editing.
This dual model, open-source innovation paired with commercial partnerships, allows Profluent to expand access to its platform while still capturing value through high-end pharmaceutical collaborations like the one with Eli Lilly.
The partnership highlights how AI is rapidly shifting from experimental use in biotech to becoming a central tool in drug discovery pipelines. As companies like Eli Lilly invest heavily in this frontier, the next breakthrough in genetic medicine may come not from a laboratory alone, but from algorithms designing biology itself.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
